ASX:BLT

Benitec Biopharma (BLT) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Benitec Biopharma

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. The company was founded in 1995 and is headquartered in Melbourne, Australia.

BLT Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive BLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Jerel A. Banks
    CEO & Exec. Chairman
  • Ms. Megan Joan Boston
    Exec. Director
  • Mr. Bryan Dulhunty
    Chief Financial Officer
  • Dr. Michael Graham
    Head of Discovery & Founding Scientist
  • Dr. Craig Lewis
    Chief Medical Adviser

This page (ASX:BLT) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners